News Column

Pyng Medical Corp. Announces Election of Directors and Officers and Approval of Stock Option Plan at 2013 Annual General Meeting

May 1 2013 12:00AM

Marketwire

LogoTracker

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 05/01/13 -- Pyng Medical Corp. (the "Company") (TSX VENTURE: PYT) announced today that at the Annual General Meeting ("AGM") of the shareholders held on April 23, 2013, the following persons were elected as directors: Robert ("Bob") Di Silvio, Dr. Ronald Blanck, L.J. ("Bud") Evans Jr., Dr. Alan L. Moloff, and Herbert A. Toms III. The Company's Stock Option Plan dated March 18, 2005, as amended March 5, 2008 and March 31, 2011, was also approved until the next AGM, subject to filing with the TSXV.

At a Board Meeting held immediately following the AGM on April 23, 2013, Dr. Blanck was elected Chairman, Mark Hodge was reappointed as President & Chief Executive Officer of the Company and George Dorin, CA was reappointed as Chief Financial Officer and Corporate Secretary. The Company's Audit and Finance Committee, and Compensation and Corporate Governance Committee were also reconstituted for the ensuing year. Both Committees have three members which include Dr. Ronald Blanck, L.J. (Bud ) Evans, and Robert Di Silvio. Dr. Blanck and Mr. Evans are considered Independent Directors.

About Pyng Medical Corp.

Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide.

Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Contacts:
Pyng Medical Corp.
George Dorin
Chief Financial Officer
(604) 303-7964 x219
www.pyng.com





Source: Marketwire